Increase of cyclooxygenase-2 inhibition with celecoxib combined with 5-FU enhances tumor cell apoptosis and antitumor efficacy in a subcutaneous implantation tumor model of human colon cancer

[1]  Z. Pan,et al.  Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  F. Severcan,et al.  Celecoxib reduces fluidity and decreases metastatic potential of colon cancer cell lines irrespective of COX-2 expression. , 2012, Bioscience reports.

[3]  B. LaFleur,et al.  Dual Blockade of the EGFR and COX-2 Pathways: A Phase II Trial of Cetuximab and Celecoxib in Patients With Chemotherapy Refractory Metastatic Colorectal Cancer , 2011, American journal of clinical oncology.

[4]  J. P. Saini,et al.  Efficacy of capecitabine versus 5-fluorouracil in colorectal and gastric cancers: a meta-analysis of individual data from 6171 patients. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  L. Xing,et al.  Observation of Curative Efficacy and Prognosis following Combination Chemotherapy with Celecoxib in the Treatment of Advanced Colorectal Cancer , 2011, The Journal of international medical research.

[6]  L. Moreira,et al.  Cyclooxygenase as a target for colorectal cancer chemoprevention. , 2011, Current drug targets.

[7]  F. Wang,et al.  Expression of COX-2 and Bcl-2 in primary fallopian tube carcinoma: correlations with clinicopathologic features. , 2011, Folia histochemica et cytobiologica.

[8]  J. Carethers,et al.  DNA mismatch repair proficiency executing 5-fluorouracil cytotoxicity in colorectal cancer cells , 2011, Cancer biology & therapy.

[9]  C. Moskaluk,et al.  Preoperative chemoradiation for rectal cancer using capecitabine and celecoxib correlated with posttreatment assessment of thymidylate synthase and thymidine phosphorylase expression. , 2011, International journal of radiation oncology, biology, physics.

[10]  C. Bocca,et al.  Antiproliferative effects of COX-2 inhibitor celecoxib on human breast cancer cell lines , 2011, Molecular and Cellular Biochemistry.

[11]  Bing Liu,et al.  Cyclo‐oxygenase 2 up‐regulates the effect of multidrug resistance , 2010, Cell biology international.

[12]  J. Engel,et al.  Treatment of feline mammary tumours using chemotherapy, surgery and a COX-2 inhibitor drug (meloxicam): a retrospective study of 23 cases (2002-2007)*. , 2009, Veterinary and comparative oncology.

[13]  A. Debucquoy,et al.  Double blind randomized phase II study with radiation+5-fluorouracil+/-celecoxib for resectable rectal cancer. , 2009, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[14]  R. Grover,et al.  Apricoxib, a COX-2 inhibitor for the potential treatment of pain and cancer. , 2009, IDrugs : the investigational drugs journal.

[15]  L. Landi,et al.  Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refractory Prostate Cancer , 2009, Clinical Cancer Research.

[16]  J. Cen,et al.  Expression of Dlk1 gene in myelodysplastic syndrome determined by microarray, and its effects on leukemia cells. , 2008, International journal of molecular medicine.

[17]  K. Mills,et al.  Therapeutic vaccination with dendritic cells pulsed with tumor-derived Hsp70 and a COX-2 inhibitor induces protective immunity against B16 melanoma. , 2008, Vaccine.

[18]  O. Laterza,et al.  Comparative Inhibitory Activity of Etoricoxib, Celecoxib, and Diclofenac on COX‐2 Versus COX‐1 in Healthy Subjects , 2008, Journal of clinical pharmacology.

[19]  H. Sasaki,et al.  Absorption and distribution characteristics of 5-fluorouracil (5-FU) after an application to the liver surface in rats in order to reduce systemic side effects. , 2008, Biological & pharmaceutical bulletin.

[20]  I. Weinstein,et al.  Celecoxib‐induced growth inhibition in SW480 colon cancer cells is associated with activation of protein kinase G , 2007, Molecular carcinogenesis.

[21]  N. Hayashi,et al.  Synergistic antitumor effects of celecoxib with 5‐fluorouracil depend on IFN‐γ , 2007, International journal of cancer.

[22]  Ying Zheng,et al.  Nicotine stimulates human lung cancer cell growth by inducing fibronectin expression. , 2007, American journal of respiratory cell and molecular biology.

[23]  P. Philip,et al.  Phase-II study of dose attenuated schedule of irinotecan, capecitabine, and celecoxib in advanced colorectal cancer , 2007, Cancer Chemotherapy and Pharmacology.

[24]  J. Rhee,et al.  Celecoxib attenuates 5-fluorouracil-induced apoptosis in HCT-15 and HT-29 human colon cancer cells. , 2007, World journal of gastroenterology.

[25]  T. Miyashita,et al.  Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. , 2006, World journal of gastroenterology.

[26]  K. Debatin,et al.  Activation of apoptosis pathways by anticancer treatment. , 2000, Toxicology letters.

[27]  John Calvin Reed,et al.  Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. , 1996, The American journal of pathology.

[28]  Wei Li,et al.  The COX-2 inhibitor Celecoxib enhances the sensitivity of KB/VCR oral cancer cell lines to Vincristine by down-regulating P-glycoprotein expression and function. , 2012, Prostaglandins & other lipid mediators.

[29]  Anastasios Stofas,et al.  World Journal of Surgical Oncology , 2007 .